Neuromyelitis Optica Spectrum Disorder Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight's, "Neuromyelitis Optica Spectrum Disorder Pipeline Insight 2026" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Neuromyelitis Optica Spectrum Disorder pipeline landscape. It covers the Neuromyelitis Optica Spectrum Disorder Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Neuromyelitis Optica Spectrum Disorder Pipeline? Click here to explore the therapies and trials making headlines @ [https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Neuromyelitis Optica Spectrum Disorder Pipeline Report

* On February 13, 2026- Hoffmann-La Roche announced a phase III study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.
* DelveInsight's Neuromyelitis Optica Spectrum Disorder Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Neuromyelitis Optica Spectrum Disorder treatment.
* The leading Neuromyelitis Optica Spectrum Disorder Companies such as Bio-Thera Solutions, Bioray Laboratories, Nanjing Bioheng Biotech Co., Ltd., Nanjing IASO Biotherapeutics, Shanghai Jiaolian Drug Research and Development Co. Ltd, Shanghai Xiniao Biotech Co., Ltd . and others.
* Promising Neuromyelitis Optica Spectrum Disorder Therapies such as Ravulizumab, B001, Eculizumab, Inebilizumab, MIL62, satralizumab, azathioprine (AZA), NPB-01, JYP0061 and others.

Want to know which companies are leading innovation in Neuromyelitis Optica Spectrum Disorder? Dive into the full pipeline insights @ Neuromyelitis Optica Spectrum Disorder Clinical Trials Assessment [https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Neuromyelitis Optica Spectrum Disorder Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Neuromyelitis Optica Spectrum Disorder Pipeline Report also highlights the unmet needs with respect to the Neuromyelitis Optica Spectrum Disorder.

Neuromyelitis Optica Spectrum Disorder Overview

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare, severe autoimmune disease of the central nervous system in which the body's immune system mistakenly attacks healthy cells in the optic nerves and spinal cord. This condition often leads to episodes of optic neuritis (causing eye pain and vision loss) and transverse myelitis (causing weakness, paralysis, sensory loss, and bladder or bowel dysfunction). Unlike multiple sclerosis, NMOSD is commonly associated with antibodies against aquaporin-4 (AQP4-IgG), which target water channel proteins on astrocytes, leading to inflammation and nerve damage.

Neuromyelitis Optica Spectrum Disorder Emerging Drugs Profile

* BAT4406F: Bio-Thera Solutions

BAT4406 is an investigational ADCC-enhanced anti-CD20 mAb candidate in clinical development for the treatment of autoimmune diseases. BAT4406F is currently being evaluated in NMOSD, an orphan indication with an estimated prevalence of 0.5 to 10 per 100,000. BAT4406 is a type I glyco-engineered mAb that binds specifically to CD20 on B-cells, kills the B-cells by CDC, and enhances ADCC effect. B cells have been implicated in the pathogenesis of a number of autoimmune diseases, including the CNS disorders, multiple sclerosis (MS) and NMOSD. Depletion of B-cells could provide meaningful relief for these autoimmune diseases. NMOSD is an autoimmune inflammatory disorder of the central nervous system (CNS) with preferential localization to the optic nerve, spinal cord and brain stem. Patients typically experience bouts of vision loss or blindness, attacks of myelitis with often severe motor impairment including loss of ambulation, sensory disturbances, bowel/bladder dysfunction, and brainstem attacks with characteristic episodes of intractable nausea, vomiting and hiccups. Currently, the drug is in Phase III stage of its development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD).

* B001: Shanghai Jiaolian Drug Research and Development Co., Ltd

B001 is a recombinant humanized antiCD20 monoclonal antibody developed by Shanghai Jiaolian Drug Research & Development (originating from Shanghai Pharmaceuticals Holding). It works by targeting CD20 on B cells and triggering antibodydependent cellular cytotoxicity (ADCC) to deplete autoreactive B cells, a mechanism aligned with current NMOSD treatment goals. Designed for intravenous administration, B001 aims to reduce disease relapses in AQP4IgG positive NMOSD through sustained Bcell suppression. It also shows potential across other autoimmune neurologic conditions and Bcell malignancies, illustrating a broad therapeutic strategy rooted in targeted immunotherapy. Currently, the drug is in Phase II/III stage of its development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD).

* CT103A cells: Nanjing IASO Biotherapeutics

Equecabtagene Autoleucel (Eque-cel) is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, and 4-1BB co-stimulatory and CD3activation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations, Eque-cel demonstrates rapid and potent efficacy, accompanied by exceptional long-term persistence in vivo, enabling patients to achieve higher and deeper responses. Currently, the drug is in Phase I stage of its development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD).

If you're tracking ongoing Neuromyelitis Optica Spectrum Disorder Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Neuromyelitis Optica Spectrum Disorder Treatment Drugs [https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Neuromyelitis Optica Spectrum Disorder Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Neuromyelitis Optica Spectrum Disorder with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuromyelitis Optica Spectrum Disorder Treatment.
* Neuromyelitis Optica Spectrum Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Neuromyelitis Optica Spectrum Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuromyelitis Optica Spectrum Disorder market.

Neuromyelitis Optica Spectrum Disorder Companies

Bio-Thera Solutions, Bioray Laboratories, Nanjing Bioheng Biotech Co., Ltd., Nanjing IASO Biotherapeutics, Shanghai Jiaolian Drug Research and Development Co. Ltd, Shanghai Xiniao Biotech Co., Ltd . and others.

Neuromyelitis Optica Spectrum Disorder Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Neuromyelitis Optica Spectrum Disorder Products have been categorized under various Molecule types such as,

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Neuromyelitis Optica Spectrum Disorder Pipeline Report covers it all - check it out now @ Neuromyelitis Optica Spectrum Disorder Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Neuromyelitis Optica Spectrum Disorder Pipeline Report

* Coverage- Global
* Neuromyelitis Optica Spectrum Disorder Companies- Bio-Thera Solutions, Bioray Laboratories, Nanjing Bioheng Biotech Co., Ltd., Nanjing IASO Biotherapeutics, Shanghai Jiaolian Drug Research and Development Co. Ltd, Shanghai Xiniao Biotech Co., Ltd . and others.
* Neuromyelitis Optica Spectrum Disorder Therapies- Ravulizumab, B001, Eculizumab, Inebilizumab, MIL62, satralizumab, azathioprine (AZA), NPB-01, JYP0061 and others.
* Neuromyelitis Optica Spectrum Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Neuromyelitis Optica Spectrum Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Neuromyelitis Optica Spectrum Disorder Treatment landscape in this detailed analysis @ Neuromyelitis Optica Spectrum Disorder Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Neuromyelitis Optica Spectrum Disorder (NMOSD): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Neuromyelitis Optica Spectrum Disorder (NMOSD)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* BAT4406F: Bio-Thera Solutions
* Mid Stage Products (Phase II/III)
* B001: Shanghai Jiaolian Drug Research and Development Co., Ltd
* Early Stage Products (Phase I)
* CT103A cells: Nanjing IASO Biotherapeutics
* Preclinical and Discovery Stage Products
* Inactive Products
* Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Companies
* Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Products
* Neuromyelitis Optica Spectrum Disorder (NMOSD)- Unmet Needs
* Neuromyelitis Optica Spectrum Disorder (NMOSD)- Market Drivers and Barriers
* Neuromyelitis Optica Spectrum Disorder (NMOSD)- Future Perspectives and Conclusion
* Neuromyelitis Optica Spectrum Disorder (NMOSD) Analyst Views
* Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuromyelitis-optica-spectrum-disorder-clinical-trial-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-domain-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.